These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34855188)

  • 1. Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection.
    Stellini R; Gianello R; Meloni A; Croce E; Materzanini P; Gomarasca W
    Infection; 2022 Jun; 50(3):791-793. PubMed ID: 34855188
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
    Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
    Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine).
    Daldoul M; Korbi M; Bellalah A; Ben Fadhel N; Belhadjali H; Zili J
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e743-e744. PubMed ID: 35604050
    [No Abstract]   [Full Text] [Related]  

  • 4. A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients.
    Masset C; Benotmane I; Dantal J; Garandeau C; Gauthier-Vargas G; Cantarovich D; Meurette A; Giral M; Caillard S; Blancho G
    Kidney Int; 2022 Apr; 101(4):825-826. PubMed ID: 35167873
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine.
    Zeng G
    Lancet Microbe; 2022 Aug; 3(8):e561. PubMed ID: 35659883
    [No Abstract]   [Full Text] [Related]  

  • 6. Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
    Wang M; Wen W; Zhou M; Wang C; Feng ZH
    Am J Cardiol; 2022 Mar; 167():155-157. PubMed ID: 35063268
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
    Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
    Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 mRNA Vaccine Short-Term Safety in Patients With Inflammatory Bowel Disease.
    Spiera E; Agrawal M; Ungaro RC
    Gastroenterology; 2022 Mar; 162(3):987-988. PubMed ID: 34626602
    [No Abstract]   [Full Text] [Related]  

  • 9. Acquired hemophilia A with SARS-CoV-2 mRNA vaccine: first case from Pakistan.
    Rashid A; Khan Z; Alam J
    Scand J Clin Lab Invest; 2022 Sep; 82(5):432-434. PubMed ID: 35767232
    [No Abstract]   [Full Text] [Related]  

  • 10. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of mRNA-Based Vaccines for SARS CoV-2.
    Barda B; Cerny A
    Chem Res Toxicol; 2021 Aug; 34(8):1823-1825. PubMed ID: 34009959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination.
    Maeda M; Isawa T; Tada N
    Circ J; 2022 Mar; 86(4):724. PubMed ID: 34866122
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of Covid-19 mRNA vaccine on serum anti-Müllerian hormone levels.
    Mohr-Sasson A; Haas J; Abuhasira S; Sivan M; Doitch Amdurski H; Dadon T; Blumenfeld S; Derazne E; Hemi R; Orvieto R; Afek A; Rabinovici J
    Hum Reprod; 2022 Mar; 37(3):534-541. PubMed ID: 34935913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Masuda T; Murakami K; Sugiura K; Sakui S; Philip Schuring R; Mori M
    Vaccine; 2022 Mar; 40(13):2044-2052. PubMed ID: 35177302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA.
    Krantz MS; Phillips EJ
    Lancet Infect Dis; 2022 Jun; 22(6):747-748. PubMed ID: 35271806
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment on D'Addio et al. Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes. Diabetes 2022;71:1800-1806.
    Sookaromdee P; Wiwanitkit V
    Diabetes; 2022 Sep; 71(9):e13. PubMed ID: 35984962
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over.
    Alicandro G; Daccó V; Cariani L; Contarini M; Morlacchi LC; Rosazza C; Sciarrabba CS; Ferraro F; Lanfranchi C; Orena BS; Gramegna A; Blasi F; Colombo C
    J Cyst Fibros; 2022 May; 21(3):e173-e175. PubMed ID: 35256306
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to Comment on D'Addio et al. Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes. Diabetes 2022;71:1800-1806.
    D'Addio F; Fiorina P
    Diabetes; 2022 Sep; 71(9):e14. PubMed ID: 35984961
    [No Abstract]   [Full Text] [Related]  

  • 20. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines.
    Chapin-Bardales J; Gee J; Myers T
    JAMA; 2021 Jun; 325(21):2201-2202. PubMed ID: 33818592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.